Sergei Tjulandin
0000-0001-9807-2229
Publication & Citation Trends
Most Cited Works
Publications
346 total
Platinum or non-platinum therapy in post-olaparib recurrent ovarian cancer: Analysis in matched cohorts.
Cited by 0
Semantic Scholar
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PDF
Cited by 734
OpenAlex
A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer OA
Cited by 7
Semantic Scholar
Agreement between FGFR2 immunohistochemistry assays and fluorescence in situ hybridization (FISH) in metastatic gastric cancer: A comparison study.
Cited by 1
Semantic Scholar
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Cited by 107
Semantic Scholar
Imbalanced censoring as a bias in evaluation of randomized controlled trials: A simulation-based study.
Cited by 0
Semantic Scholar
Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.
Cited by 6
Semantic Scholar
Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. OA
Cited by 6
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(65)
Gastric Cancer Management and Outcomes
(62)
Cancer Treatment and Pharmacology
(47)
Lung Cancer Treatments and Mutations
(46)
HER2/EGFR in Cancer Research
(43)
Frequent Co-Authors
Affiliations
Roche (Switzerland)
Universitat Autònoma de Barcelona
National Health Service
BC Cancer Agency
Academy of Medical Sciences